Contineum Therapeutics, Inc. (CTNM)
9.86
+0.08
(+0.82%)
USD |
NASDAQ |
Nov 13, 16:00
9.885
+0.02
(+0.25%)
After-Hours: 19:59
Contineum Therapeutics Enterprise Value : 148.78M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 148.78M |
| November 12, 2026 | 145.64M |
| November 11, 2026 | 184.50M |
| November 10, 2026 | 176.26M |
| November 09, 2026 | 166.05M |
| November 06, 2026 | 135.44M |
| November 05, 2026 | 107.57M |
| November 04, 2026 | 146.03M |
| November 03, 2026 | 142.11M |
| November 02, 2026 | 137.01M |
| October 30, 2026 | 130.33M |
| October 29, 2026 | 127.98M |
| October 28, 2026 | 120.91M |
| October 27, 2026 | 114.64M |
| October 26, 2026 | 81.27M |
| October 23, 2026 | 87.95M |
| October 22, 2026 | 91.28M |
| October 21, 2026 | 89.52M |
| October 20, 2026 | 93.83M |
| October 19, 2026 | 53.80M |
| October 16, 2026 | 39.67M |
| October 15, 2026 | 71.85M |
| October 14, 2026 | 81.27M |
| October 13, 2026 | 92.26M |
| October 12, 2026 | 97.95M |
| Date | Value |
|---|---|
| October 09, 2026 | 286.94M |
| October 08, 2026 | 279.09M |
| October 07, 2026 | 261.43M |
| October 06, 2026 | 258.29M |
| October 05, 2026 | 261.04M |
| October 02, 2026 | 276.74M |
| October 01, 2026 | 271.63M |
| September 30, 2026 | 288.51M |
| September 29, 2026 | 202.58M |
| September 28, 2026 | 248.84M |
| September 25, 2026 | 242.45M |
| September 24, 2026 | 239.81M |
| September 23, 2026 | 240.57M |
| September 22, 2026 | 274.04M |
| September 21, 2026 | 279.68M |
| September 18, 2026 | 278.93M |
| September 17, 2026 | 266.90M |
| September 16, 2026 | 287.58M |
| September 15, 2026 | 289.84M |
| September 14, 2026 | 327.45M |
| September 11, 2026 | 327.45M |
| September 10, 2026 | 321.44M |
| September 09, 2026 | 339.49M |
| September 08, 2026 | 369.58M |
| September 04, 2026 | 398.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.61M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -104.09M |
| Fulcrum Therapeutics, Inc. | -12.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.70M |
| Total Expenses (Quarterly) | 18.70M |
| EPS Diluted (Quarterly) | -0.487 |
| Earnings Yield | -17.95% |
| Normalized Earnings Yield | -17.95 |